Invest Now
Samco Star Rating Ads

Glenmark Pharmaceuticals Ltd Price Performance

  • Day's Low
  • ₹1,504.55
  • Day's High
  • ₹1,530.10
₹ 1,514.15
  • 52-w low
  • ₹771
  • 52-w high
  • ₹1,830.95
1,514.15
  • Day's open
    ₹1,528
  • Previous close
    ₹1,528.10
  • VWAP
    ₹1,515.31
  • Lower price band
    ₹1,362.75
  • Upper price band
    ₹1,665.55

Today's Market Action

The last traded share price of Glenmark Pharmaceuticals Ltd was 1,514.15 down by -0.91% on the NSE. Its last traded stock price on BSE was 1,520 down by -0.54%. The total volume of shares on NSE and BSE combined was 376,757 shares. Its total combined turnover was Rs 57.09 crores.

Glenmark Pharmaceuticals Ltd Medium and Long Term Market Action

Glenmark Pharmaceuticals Ltd hit a 52-week high of 1,830.95 on 15-10-2024 and a 52-week low of 771 on 15-02-2024. The stock price of Glenmark Pharmaceuticals Ltd is down by -9% over the last one month. It is up by 89.96% over the last one year. Don't forget to check the full stock price history in the table below.

Glenmark Pharmaceuticals Ltd Fundamentals

  • Market Cap (Cr): 43279

  • Book Value (₹):

  • Stock P/E:

  • Revenue (Cr):

  • Total Debt (Cr):

  • Face Value (₹):

  • Roce (%):

  • ROE (%):

  • Earnings (Cr):

  • Promoter’s Holdings (%):

  • EPS (₹):

  • Debt to Equity:

  • Dividend Yield (%):

  • Cash (Cr):

Glenmark Pharmaceuticals Ltd Mutual fund holdings and trends

FUND NAME Quantity Monthly Change (Qty)

Glenmark Pharmaceuticals Ltd Shareholding Pattern

Similar Stocks

Company Price Market Cap (Cr) P/E

About Glenmark Pharmaceuticals Ltd

Data not available.

Glenmark Pharmaceuticals Ltd FAQ's

What is Share Price of Glenmark Pharmaceuticals Ltd?

What is the Market Cap of Glenmark Pharmaceuticals Ltd?

What is PE Ratio of Glenmark Pharmaceuticals Ltd?

What is PB Ratio of Glenmark Pharmaceuticals Ltd?

What is the CAGR of Glenmark Pharmaceuticals Ltd?

How to Buy Glenmark Pharmaceuticals Ltd Share?

Financials

(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

News

Review

Pros

  • Momentum Strength
    The stock is currently exhibiting strong momentum, & is showing consistent strong relative strength.

Cons

  • Low Sustainable RoE
    The company's sustainable return on equity is lower than the expected cost of capital which implies that the underlying business will destruct value over a period of time due to it's inability to generate superior returns on capital.
  • Low Return on Capital Employed
    The company is unable to generate sufficient return on capital employed which impairs it's ability to generate high return for shareholders after accounting for taxes, interest and other non-equity stakeholders.
  • Poor Cash Flow Conversion
    The business has very poor cash conversion ratio of only -17.30% of operating earnings getting converted into operating cash flow. This implies that increase in profits has not translated into higher cash flows for the business and incrementally higher investments in working capital which works negatively for shareholders.
  • Low Interest Coverage
    The company has a very low Interest coverage ratio of 2.32 times which implies that a large portion of operating profits are getting attributed to payment of interest to debtholders. This leaves lower earnings and cash flows for equity shareholders which is negative for returns.
  • Highly Cyclical Industry
    The company operates an extremely cyclical business with unpredictable earnings and cash flows. This shall result in very high stock price volatility and returns which would negatively impact shareholder returns.
  • Poor Working Capital Cycle
    The company has a very poor working capital cycle of 132 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.

Valuation Analysis

Margin of safety
(10/12/2024)
Stock Valuation
Green line
93
84.21%
84.21% People are bullish about Glenmark Pharmaceuticals Ltd
15.79%
15.79 % People are bearish about Glenmark Pharmaceuticals Ltd

What is your opinion about this Stock?

Historical Data

Samco Star Rating Ads

Glenmark Pharmaceuticals Ltd

1,514.15 -13.95 (-0.91%)

Brokerage & Taxes at Samco

Brokerage & Taxes at Other traditional broker

Potential Brokerage Savings with Samco ₹ 49.62()

Top Gainers (NIFTY 50)

Stock Name Change %

    Top Losers (NIFTY 50)

    Stock Name Change %

      Open Free Account Now
      Open a Demat Account

      Free Trading & Demat Account

      +91